1. Home
  2. TSLX vs HRMY Comparison

TSLX vs HRMY Comparison

Compare TSLX & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TSLX
  • HRMY
  • Stock Information
  • Founded
  • TSLX 2010
  • HRMY 2017
  • Country
  • TSLX United States
  • HRMY United States
  • Employees
  • TSLX N/A
  • HRMY N/A
  • Industry
  • TSLX Investment Managers
  • HRMY Biotechnology: Pharmaceutical Preparations
  • Sector
  • TSLX Finance
  • HRMY Health Care
  • Exchange
  • TSLX Nasdaq
  • HRMY Nasdaq
  • Market Cap
  • TSLX 2.1B
  • HRMY 2.0B
  • IPO Year
  • TSLX 2014
  • HRMY 2020
  • Fundamental
  • Price
  • TSLX $23.81
  • HRMY $32.04
  • Analyst Decision
  • TSLX Strong Buy
  • HRMY Strong Buy
  • Analyst Count
  • TSLX 8
  • HRMY 9
  • Target Price
  • TSLX $22.69
  • HRMY $54.22
  • AVG Volume (30 Days)
  • TSLX 544.2K
  • HRMY 627.2K
  • Earning Date
  • TSLX 07-30-2025
  • HRMY 08-05-2025
  • Dividend Yield
  • TSLX 8.73%
  • HRMY N/A
  • EPS Growth
  • TSLX N/A
  • HRMY 13.13
  • EPS
  • TSLX 1.89
  • HRMY 2.62
  • Revenue
  • TSLX $481,092,000.00
  • HRMY $744,852,000.00
  • Revenue This Year
  • TSLX N/A
  • HRMY $20.10
  • Revenue Next Year
  • TSLX N/A
  • HRMY $18.01
  • P/E Ratio
  • TSLX $12.62
  • HRMY $12.13
  • Revenue Growth
  • TSLX 4.73
  • HRMY 20.62
  • 52 Week Low
  • TSLX $18.58
  • HRMY $26.47
  • 52 Week High
  • TSLX $23.98
  • HRMY $41.61
  • Technical
  • Relative Strength Index (RSI)
  • TSLX 61.00
  • HRMY 38.57
  • Support Level
  • TSLX $22.76
  • HRMY $31.25
  • Resistance Level
  • TSLX $23.25
  • HRMY $32.46
  • Average True Range (ATR)
  • TSLX 0.34
  • HRMY 1.00
  • MACD
  • TSLX -0.06
  • HRMY -0.37
  • Stochastic Oscillator
  • TSLX 83.22
  • HRMY 11.69

About TSLX Sixth Street Specialty Lending Inc.

Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Share on Social Networks: